Form 4: Corbus CEO Yuval Cohen Granted New Equity Awards

Corbus Pharmaceuticals Holdings CEO Yuval Cohen received 50,000 restricted stock units and 150,000 stock options as part of his compensation package.

Summary

• Corbus Pharmaceuticals Holdings, Inc. CEO Yuval Cohen was granted 50,000 restricted stock units (RSUs) and 150,000 stock options on January 14, 2026.
• The RSUs will be settled in common stock and vest 25% annually on the first, second, third, and fourth anniversaries starting January 14, 2027.
• A prorata portion of RSUs may accelerate upon termination without cause after the first vesting date.
• The stock options have an exercise price of $8.26 and vest 25% on January 14, 2027, with the remaining 75% vesting in equal monthly installments over 36 months commencing on February 14, 2027.
• The option award was made under the issuer's 2024 Equity Compensation Plan.
• Following these transactions, Mr. Cohen beneficially owns 188,187 shares of common stock (including 173,561 unvested RSUs) and 150,000 stock options.

Sentiment

Score: 7

Explanation: The grant of equity compensation to the CEO is a positive signal of alignment between management and shareholder interests, providing long-term incentives. It's a routine compensation event, not a major market catalyst, hence a moderately positive score.

Positives

• The grant of equity to the CEO aligns management's interests with those of shareholders, promoting long-term value creation.
• The equity compensation plan provides long-term incentives for executive performance and retention.

Negatives

• No specific negatives are identified in this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The multi-year vesting schedules for both RSUs and stock options indicate a long-term commitment from the CEO to the company's future performance and growth, aligning executive incentives with shareholder value creation over several years.

Industry Context

Executive equity compensation, such as RSUs and stock options, is a standard practice across the biotechnology and pharmaceutical industries. These grants are crucial for attracting, retaining, and incentivizing key leadership, ensuring their interests are aligned with the long-term strategic goals and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of multi-year vesting for equity awards is a common industry practice designed to promote long-term executive retention and performance alignment.
• The specific number of units and exercise price would typically be benchmarked against peer companies in the biotechnology sector, considering company size, stage of development, and executive role, though specific comparative data is not provided in this filing.

Corporate Governance

Related Party Transactions

• The equity grant to the CEO is a standard compensation arrangement and is disclosed as an insider transaction, which is a routine form of related party dealing within executive compensation frameworks.

Stakeholder Impact

• Shareholders: The equity grant aims to align the CEO's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Continued service by the CEO to meet vesting conditions for RSUs and stock options.
• Future vesting events for the granted equity awards on their respective schedules.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Yuval Cohen, Form 4, SEC filing, restricted stock units, RSUs, stock options, equity compensation, insider transaction, CEO compensation